Soft tissue sarcomas (STS) are rare malignancies of mesenchymal origin comprising ∼1% of all adult cancers. According to the 2013 updated World Health Organization (WHO) classification STS represents a highly heterogeneous tumor entity of more than 50 subtypes showing very distinct histologic, molecular and certainly clinical characteristics [1]. Surgery is the mainstay of treatment of localized disease, however, around 50% of patients experience metastatic recurrence during the course of their disease. This disease stage is still characterized by an unfavorable prognosis and a median overall survival of ∼12–15 months [2, 3]. Due to conflicting data, adjuvant chemotherapy is not a standard treatment in STS in adulthood [4], but may be offered to the cohort of high-risk patients—tumor size >5 cm, deep localization, G2/3—after detailed patient information and shared-decision making. However, in spite of numerous studies, we are still missing strong prognostic markers to predict patients’ outcome.

中文翻译：

---

局部软组织肉瘤患者的结果预测：哪种工具是最好的？

软组织肉瘤（STS）是间充质起源的罕见恶性肿瘤，约占所有成人癌症的1％。根据2013年更新的世界卫生组织（WHO）分类，STS代表了高度异质性的肿瘤实体，具有50多个亚型，表现出非常独特的组织学，分子学和临床特征[1]。手术是局部疾病治疗的主要手段，但是，约有50％的患者在病程中经历转移性复发。该疾病阶段的特征仍然是预后不良，中位总生存期约为12-15个月[2，3]。由于数据矛盾，辅助化疗不是成年期STS的标准治疗方法[4]，但可能会提供给高危患者队列使用-肿瘤大小> 5 cm，深层定位，G2 / 3-在详细的患者信息和共同决策之后。然而，尽管进行了大量研究，但我们仍然缺少强有力的预后指标来预测患者的预后。